SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 44 filers reported holding SUNESIS PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $1,109,000 | -37.4% | 4,212,833 | -1.3% | 0.00% | – |
| Q1 2020 | $1,772,000 | +27.0% | 4,269,729 | +3.3% | 0.00% | – |
| Q4 2019 | $1,395,000 | -53.1% | 4,132,122 | 0.0% | 0.00% | – |
| Q3 2019 | $2,975,000 | +79.2% | 4,132,122 | +81.0% | 0.00% | – |
| Q2 2019 | $1,660,000 | +96.2% | 2,283,383 | +228.0% | 0.00% | – |
| Q1 2019 | $846,000 | +389.0% | 696,226 | +67.3% | 0.00% | – |
| Q4 2018 | $173,000 | -92.2% | 416,257 | -62.3% | 0.00% | – |
| Q3 2018 | $2,208,000 | -7.0% | 1,103,913 | -1.4% | 0.00% | – |
| Q2 2018 | $2,373,000 | -25.2% | 1,119,114 | -4.1% | 0.00% | – |
| Q1 2018 | $3,172,000 | -15.1% | 1,166,417 | +15.1% | 0.00% | – |
| Q4 2017 | $3,738,000 | +219.5% | 1,013,009 | +67.9% | 0.00% | – |
| Q3 2017 | $1,170,000 | -28.4% | 603,341 | -0.4% | 0.00% | – |
| Q2 2017 | $1,635,000 | -31.5% | 605,759 | +4.1% | 0.00% | – |
| Q1 2017 | $2,386,000 | +52.9% | 581,940 | +35.0% | 0.00% | – |
| Q4 2016 | $1,560,000 | -8.8% | 430,946 | +10.0% | 0.00% | – |
| Q3 2016 | $1,711,000 | – | 391,611 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 2,600,000 | $1,092,000 | 1.15% |
| BVF INC/IL | 2,287,860 | $951,000 | 0.12% |
| Eventide Asset Management | 2,265,455 | $942,000 | 0.04% |
| SABBY MANAGEMENT, LLC | 400,140 | $166,000 | 0.04% |
| RP Management, LLC | 129,517 | $54,000 | 0.04% |
| Palo Alto Investors LP | 1,162,473 | $483,000 | 0.03% |
| NEA Management Company, LLC | 1,298,274 | $539,000 | 0.02% |
| Rhenman & Partners Asset Management AB | 377,244 | $157,000 | 0.02% |
| GREAT POINT PARTNERS LLC | 317,962 | $132,000 | 0.02% |
| Vivo Capital, LLC | 195,474 | $81,000 | 0.01% |